Registr prospektivních výsledků idiopatické plicní fibrózy a intersticiálního plicního onemocnění (IPF/ILD-PRO)
Registr prospektivních výsledků idiopatické plicní fibrózy (IPF-PRO) a chronického fibrotizujícího intersticiálního plicního onemocnění s progresivním fenotypem (IPF-PRO/ILD-PRO)
The Idiopathic Pulmonary Fibrosis Prospective Outcomes (IPF-PRO) Registry started recruiting in 2014 with the objective of studying Idiopathic Pulmonary Fibrosis. In 2018, the registry expanded to include recruitment of participants with other chronic fibrosing interstitial lung diseases (ILDs) with progressive phenotype also referred to as progressive fibrosing interstitial lung diseases in the Chronic Fibrosis Interstitial Lung Disease with Progressive Phenotype (ILD-PRO) Registry. When the third phase of the registry begins, the IPF-PRO registry will enroll additional patients with idiopathic pulmonary fibrosis. This IPF-PRO registry is a prospective registry that will collect information regarding the natural history, health care interactions, participant reported questionnaire data to assess quality of life, and the methods of treatment of participants with a diagnosis of idiopathic pulmonary fibrosis (IPF) or of another chronic fibrosing interstitial lung disease (ILD) with progressive phenotype established at the enrolling centers. In addition, blood samples and chest image studies will be collected and banked for future research projects.
Přehled studie
Postavení
Postavení
Podmínky
Podmínky
Detailní popis
This registry originally enrolled a total of 1002 participants newly diagnosed with IPF and continues to enroll patients with other chronic fibrosing ILDs with newly identified progressive phenotype to reach an enrollment of 1000 patients. Participants will be enrolled in three phases, (IPF-PRO and ILD-PRO) over a span of 8 years at approximately 50 sites experienced in the diagnosis and treatment of ILD in the United States. Enrollment for the original IPF cohort started in 2014 and ended in October 2018, with 1002 total participants enrolled. In the third phase of the registry new enrollment for patients with IPF will restart in 2023-2024 with the plan to enroll up to 1000 new IPF patients, for a total IPF enrollment of 2000. Enrollment for other chronic fibrosing ILDs with newly identified progressive phenotype cohort was initiated in February 2019 and will end when enrollment reaches 1000 participants with the potential of enrolling another 1000 participants with other chronic fibrosing ILDs with newly identified without a progressive phenotype. Data and samples will be collected from participants for approximately 5 years for the IPF cohort. For the chronic fibrosing ILD with progressive phenotype cohort, data and samples will be collected for a minimum of 3 years, up to approximately 5 years. Participant management and treatment decisions will be determined by participants and their health care professionals.
Typ studie
Typ studie
Zápis (Odhadovaný)
Zápis
Kontakty a umístění
Studijní kontakt
Studijní kontakt
- Jméno: Rosalia Blanco
- Telefonní číslo: 919-660-0890
- E-mail: rosalia.blanco@duke.edu
Studijní místa
-
-
Alabama
-
Birmingham, Alabama, Spojené státy, 35294
- Nábor
- University of Alabama - Birmingham
-
Vrchní vyšetřovatel:
- Tejaswini Kulkarni, MD
-
Kontakt:
- Arnissa Hopson
- Telefonní číslo: 205-934-1657
- E-mail: agoggins@uabmc.edu
-
-
Arizona
-
Tucson, Arizona, Spojené státy, 85721
- Nábor
- University of Arizona
-
Vrchní vyšetřovatel:
- Sally A Suliman, MD
-
Kontakt:
- Daniel Castaneda-Beltran
- Telefonní číslo: 602-827-2347
- E-mail: dcastanedabeltra@arizona.edu
-
-
California
-
Los Angeles, California, Spojené státy, 90033
- Nábor
- University of Southern California
-
Kontakt:
- Lynn Fukusima
- E-mail: Lynn.Fukushima@med.usc.edu
-
Vrchní vyšetřovatel:
- Toby Maher, MD
-
Los Angeles, California, Spojené státy, 90024
- Nábor
- University of California - Los Angeles
-
Vrchní vyšetřovatel:
- John Belperio, MD
-
Kontakt:
- Stephanie Roblero
- Telefonní číslo: 310-627-2319
- E-mail: sroblero@mednet.ucla.edu
-
Stanford, California, Spojené státy, 94305
- Nábor
- Stanford University
-
Vrchní vyšetřovatel:
- Rishi Raj, MD
-
Kontakt:
- Summer Zhu
- Telefonní číslo: 650-724-5424
- E-mail: szhuye@stanford.edu
-
-
Colorado
-
Aurora, Colorado, Spojené státy, 80045
- Nábor
- University of Colorado
-
Vrchní vyšetřovatel:
- Joyce Lee, MD
-
Kontakt:
- Olivia Brohl
- Telefonní číslo: 303-724-0641
- E-mail: Olivia.brohl@cuanschutz.edu
-
-
Connecticut
-
New Haven, Connecticut, Spojené státy, 06520
- Nábor
- Yale University
-
Vrchní vyšetřovatel:
- Mridu Gulati, MD
-
Kontakt:
- Maksym Minasyan
- Telefonní číslo: 203-785-4177
- E-mail: maksym.minasyan@yale.edu
-
-
Florida
-
Gainesville, Florida, Spojené státy, 32610-3175
- Nábor
- University of Florida
-
Kontakt:
- Lisbetty Lugo
- E-mail: lisbetty.lugo@medicine.ufl.edu
-
Vrchní vyšetřovatel:
- Diana Gomez Manjarres, MD
-
Tampa, Florida, Spojené státy, 33606
- Nábor
- University of South Florida
-
Vrchní vyšetřovatel:
- Jose D Herazo-Maya, MD
-
Kontakt:
- Natasha Brown
- E-mail: nbrown@tgh.org
-
-
Georgia
-
Atlanta, Georgia, Spojené státy, 30322
- Nábor
- Emory University
-
Kontakt:
- Tracy Halabi
- Telefonní číslo: 404-712-7458
- E-mail: tracy.halaby@emory.edu
-
Vrchní vyšetřovatel:
- Srihari Veeraraghavan, MD
-
Austell, Georgia, Spojené státy, 30106
- Nábor
- Piedmont Healthcare
-
Vrchní vyšetřovatel:
- Amy Case, MD
-
Kontakt:
- Munachi (Muna) Iwotor
- Telefonní číslo: 404-291-9062
- E-mail: munachi.iwotor@piedmont.org
-
-
Illinois
-
Chicago, Illinois, Spojené státy, 60637
- Nábor
- University of Chicago
-
Vrchní vyšetřovatel:
- Mary Strek, MD
-
Kontakt:
- Vanita Patel
- E-mail: vpatel4@bsd.uchicago.edu
-
Evanston, Illinois, Spojené státy, 60611
- Nábor
- Northwestern University
-
Kontakt:
- Phillip Cooper
- Telefonní číslo: 312-503-0406
- E-mail: p-cooper@northwestern.edu
-
Vrchní vyšetřovatel:
- Bradford Bemiss, MD
-
Maywood, Illinois, Spojené státy, 60153
- Nábor
- Loyola University Health System
-
Vrchní vyšetřovatel:
- Daniel Dilling, MD
-
Kontakt:
- Sloan White
- E-mail: swhite29@luc.edu
-
-
Kansas
-
Kansas City, Kansas, Spojené státy, 66160
- Ukončeno
- University of Kansas
-
-
Kentucky
-
Lexington, Kentucky, Spojené státy, 40536
- Nábor
- University of Kentucky
-
Vrchní vyšetřovatel:
- Girish Nair, MD
-
Kontakt:
- Kai Su
- Telefonní číslo: 859-257-4501
- E-mail: kai.su@uky.edu
-
-
Louisiana
-
New Orleans, Louisiana, Spojené státy, 70112
- Nábor
- Tulane University
-
Vrchní vyšetřovatel:
- Joe Lasky, MD
-
Kontakt:
- Sandy Ditta
- Telefonní číslo: 504-988-4040
- E-mail: sditta@tulane.edu
-
-
Michigan
-
Ann Arbor, Michigan, Spojené státy, 48109
- Aktivní, ne nábor
- University of Michigan
-
Detroit, Michigan, Spojené státy, 48202
- Nábor
- Henry Ford Health
-
Kontakt:
- Deepti Naidu
- Telefonní číslo: 313-916-8732
- E-mail: dnaidu1@HFHS.ORG
-
Vrchní vyšetřovatel:
- Asif Abdul Hameed, MD
-
-
Minnesota
-
Minneapolis, Minnesota, Spojené státy, 55455
- Nábor
- University of Minnesota
-
Kontakt:
- Mandi DeGrote
- Telefonní číslo: 612-626-7609
- E-mail: carl1032@umn.edu
-
Vrchní vyšetřovatel:
- Hyum Kim, MD
-
-
Mississippi
-
Jackson, Mississippi, Spojené státy, 39216
- Nábor
- University of Mississippi Medical Center
-
Vrchní vyšetřovatel:
- Kimberly Dobbs, MD
-
Kontakt:
- Leadeashia Brackett
- Telefonní číslo: 601-496-7814
- E-mail: lbrackett@umc.edu
-
-
Missouri
-
St Louis, Missouri, Spojené státy, 63110
- Nábor
- Washington University
-
Vrchní vyšetřovatel:
- Tonya Russell, MD
-
Kontakt:
- Mona Noroozi
- Telefonní číslo: 314-362-3705
- E-mail: mnoroozi@wustl.edu
-
-
New York
-
New York, New York, Spojené státy, 10065
- Nábor
- Weill Medical College of Cornell University
-
Vrchní vyšetřovatel:
- Kerri Aronson, MD
-
Kontakt:
- Alicia Morris
- Telefonní číslo: 646-692-2741
- E-mail: ajm2017@med.cornell.edu
-
New York, New York, Spojené státy, 10016
- Aktivní, ne nábor
- NYU Medical Center
-
-
North Carolina
-
Chapel Hill, North Carolina, Spojené státy, 27514
- Nábor
- UNC Chapel Hill
-
Vrchní vyšetřovatel:
- Jason Lobo, MD
-
Kontakt:
- Jackson Pettee
- E-mail: Jackson_pettee@med.unc.edu
-
Durham, North Carolina, Spojené státy, 27705
- Nábor
- Duke University
-
Vrchní vyšetřovatel:
- Lake Morrison, MD
-
Kontakt:
- Lauren Gray
- Telefonní číslo: 919-684-7317
- E-mail: lauren.gray@duke.edu
-
Greensboro, North Carolina, Spojené státy, 27403
- Nábor
- Pulmonix LLC
-
Vrchní vyšetřovatel:
- Murali Ramaswamy, MD
-
Kontakt:
- Mei Zheng
- Telefonní číslo: 336-522-8870
- E-mail: mei.zheng@pulmonix.com
-
Wilmington, North Carolina, Spojené státy, 28401
- Ukončeno
- PMG Research
-
Winston-Salem, North Carolina, Spojené státy, 27157
- Nábor
- Wake Forest Baptist Health
-
Kontakt:
- Bob Hmieleski
- Telefonní číslo: 336-713-8550
- E-mail: bhmieles@wakehealth.edu
-
Vrchní vyšetřovatel:
- Andrew Namen, MD
-
-
Ohio
-
Cincinnati, Ohio, Spojené státy, 45267
- Aktivní, ne nábor
- University of Cincinnati Medical Center
-
Cleveland, Ohio, Spojené státy, 44195
- Nábor
- Cleveland Clinic
-
Vrchní vyšetřovatel:
- Brian Southern, MD
-
Kontakt:
- Ron Wehrmann
- Telefonní číslo: 2164450574
- E-mail: wehrmar@ccf.org
-
Columbus, Ohio, Spojené státy, 43210
- Nábor
- The Ohio State University
-
Kontakt:
- Benjamin Hood
- E-mail: benjamin.hood2@osumc.edu
-
Vrchní vyšetřovatel:
- John Odackal
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Spojené státy, 73104
- Nábor
- University of Oklahoma
-
Vrchní vyšetřovatel:
- Jad Kebbe, MD
-
Kontakt:
- Maria Mason
- Telefonní číslo: 405-271-6173
- E-mail: maria-l-mason@ouhsc.edu
-
-
Oregon
-
Portland, Oregon, Spojené státy, 97220
- Nábor
- Oregon Clinic
-
Vrchní vyšetřovatel:
- David Hotchkin, MD
-
Kontakt:
- Meg Day
- Telefonní číslo: 503-963-3182
- E-mail: mday@orclinic.com
-
-
Pennsylvania
-
Hershey, Pennsylvania, Spojené státy, 17033
- Nábor
- Penn State College of Medicine - Hershey
-
Vrchní vyšetřovatel:
- Rebecca Bascom, MD
-
Kontakt:
- Tim Sheehan
- Telefonní číslo: 717-531-2925
- E-mail: tsheehan@pennstatehealth.psu.edu
-
Philadelphia, Pennsylvania, Spojené státy, 19140
- Nábor
- Temple University
-
Vrchní vyšetřovatel:
- Rachel Criner, MD
-
Kontakt:
- Luis Cardenas-Osorio
- Telefonní číslo: 215-707-3311
- E-mail: Luis.Cardenas-Osorio@tuhs.temple.edu
-
Philadelphia, Pennsylvania, Spojené státy, 19144
- Nábor
- Thomas Jefferson University
-
Vrchní vyšetřovatel:
- Ross Summer, MD
-
Kontakt:
- Ramya Talluri, BSN, RN
- E-mail: RamyaPriya.Talluri@jefferson.edu
-
-
South Carolina
-
Charleston, South Carolina, Spojené státy, 29425
- Nábor
- Medical University of South Carolina
-
Vrchní vyšetřovatel:
- Timothy Whelan, MD
-
Kontakt:
- Audra Wiser
- E-mail: wisera@musc.edu
-
-
Tennessee
-
Nashville, Tennessee, Spojené státy, 37232
- Nábor
- Vanderbilt University
-
Kontakt:
- James Del Greco
- Telefonní číslo: 615-343-7068
- E-mail: james.del.greco@vumc.org
-
Vrchní vyšetřovatel:
- Justin Hewlett, MD
-
-
Texas
-
Dallas, Texas, Spojené státy, 75235
- Nábor
- University of Texas Southwestern
-
Vrchní vyšetřovatel:
- John Fitzgerald, MD
-
Kontakt:
- Meagan Galvan
- Telefonní číslo: 214-645-6489
- E-mail: Maegan.Galvan@UTSouthwestern.edu
-
Dallas, Texas, Spojené státy, 75246
- Nábor
- Baylor University Medical Center at Dallas
-
Vrchní vyšetřovatel:
- Yolanda Mageto, MD
-
Kontakt:
- Mary Alayo
- Telefonní číslo: 214-820-6276
- E-mail: Mary.Alayo@BSWHealth.org
-
Houston, Texas, Spojené státy, 77030
- Nábor
- Baylor College of Medicine
-
Vrchní vyšetřovatel:
- Ivan Rosas, MD
-
Kontakt:
- Maria C Perea
- E-mail: Maria.Perea@bcm.edu
-
Houston, Texas, Spojené státy, 77030
- Nábor
- Houston Methodist Lung Center
-
Vrchní vyšetřovatel:
- Zeenat Safdar, MD
-
Kontakt:
- Laura Valecillos Loukidis
- Telefonní číslo: 346-238-4637
- E-mail: lvvalecillosloukidis@houstonmethodist.org
-
Houston, Texas, Spojené státy, 77030
- Nábor
- The University of Texas Health Science Center At Houston
-
Vrchní vyšetřovatel:
- Rodeo Abrencillo, MD
-
Kontakt:
- Beverly Rios
- Telefonní číslo: 713-486-6152
- E-mail: Beverly.Rios@uth.tmc.edu
-
-
Utah
-
Salt Lake City, Utah, Spojené státy, 84108
- Nábor
- University of Utah
-
Kontakt:
- Adeline Langer
- Telefonní číslo: 801-581-5811
- E-mail: adeline.langer@hsc.utah.edu
-
Vrchní vyšetřovatel:
- Mary Beth Langer, MD
-
Salt Lake City, Utah, Spojené státy, 84111
- Nábor
- Intermountain Health
-
Kontakt:
- Aisha Skowyra
- Telefonní číslo: 801-507-2439
- E-mail: Aisha.fairclough@imail.org
-
Vrchní vyšetřovatel:
- Erin Blackstock, MD
-
-
Vermont
-
Colchester, Vermont, Spojené státy, 05446
- Aktivní, ne nábor
- University of Vermont Lung Center
-
-
Virginia
-
Charlottesville, Virginia, Spojené státy, 22908
- Aktivní, ne nábor
- University from Virginia
-
Falls Church, Virginia, Spojené státy, 22042-3307
- Nábor
- Inova Health Care Services
-
Kontakt:
- Taruni Maganti
- Telefonní číslo: 703-776-3230
- E-mail: Taruni.Maganti@inova.org
-
Vrchní vyšetřovatel:
- Jared Wilkinson, MD
-
-
Wisconsin
-
Milwaukee, Wisconsin, Spojené státy, 53226
- Aktivní, ne nábor
- The Medical College of Wisconsin
-
-
Kritéria účasti
Kritéria způsobilosti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Metoda odběru vzorků
Studijní populace
Subjects with a new diagnosis of IPF or a non- IPF chronic fibrosing ILD established at the time of enrollment in the registry are eligible for participation in the IPF-PRO/ILD-PRO registry if the participant meets the selection criteria.
Popis
Inclusion Criteria:
-
Willing and able to provide informed consent
-
Established a new diagnosis (within 12 months) of IPF by the enrolling center.
-
Age 21 years or older, or
-
Diagnosis of a non-IPF ILD of any duration, including, but not limited to Idiopathic Non-Specific Interstitial Pneumonia (iNSIP), Unclassifiable Idiopathic Interstitial Pneumonias (IIPs), Interstitial Pneumonia with Autoimmune Features (IPAF), Autoimmune ILDs such as Rheumatoid Arthritis (RA-ILD) and Systemic Sclerosis (SSc-ILD), Chronic Hypersensitivity Pneumonitis (HP), Sarcoidosis or Exposure-related ILDs such as asbestosis with progressive phenotype during the last 24 months by the enrolling center that meets the following criteria:
-
Chronic fibrosing ILD as defined by reticular abnormality with traction bronchiectasis with or without honeycombing confirmed by chest HRCT scan and/or lung biopsy.
-
Progressive phenotype as defined by fulfilling at least one of the criteria below of fibrotic changes (progression set point) within the last 24 months regardless of treatment considered appropriate in individual ILDs (8):
- decline in FVC % predicted (% pred) based on ≥10% relative decline
- decline in FVC % pred based on ≥5 - <10% relative decline in FVC combined with worsening of respiratory symptoms as assessed by the site investigator
- decline in FVC % pred based on ≥5 - <10% relative decline in FVC combined with increasing extent of fibrotic changes on chest imaging (HRCT scan) as assessed by the site investigator
- decline in DLCO % pred based on≥ 10% relative decline
- worsening of respiratory symptoms as well as increasing extent of fibrotic changes on chest imaging (HRCT scan) as assessed by the site investigator independent of FVC change.
-
The relative decline for FVC % predicted is calculated using the formula:
Relative Decline= (FVC % Pred (Reference)-FVC % Pred (Screening))/(FVC % Pred (Reference))×100%, where FVC % Pred (Reference) is the greatest measurement of FVC % predicted in the 24 months prior to screening and FVC % Pred (Screening) is the measurement of FVC % predicted at screening.
The relative decline for DLCO % predicted is calculated using the formula:
Relative Decline= (DLCO % Pred (Reference)-DLCO % Pred (Screening))/(DLCO % Pred (Reference))×100%, Where DLCO % Pred (Reference) is the greatest measurement of DLCO % Pred in the 24 months prior to screening and DLCO % Pred (Screening) is the measurement of DLCO % Pred at screening
Exclusion Criteria:
- Malignancy, treated or untreated, other than skin or early -stage prostate cancer, within the past 5 years
- Currently listed for lung transplantation at the time of enrollment
- Currently enrolled in an interventional clinical trial at the time of enrollment in this registry
- For the additional IPF cohort of 1000 individuals, previous enrollment in this registry.
Studijní plán
Jak je studie koncipována?
Detaily designu
- Observační modely: COHORT
- Časové perspektivy: PROSPECTIVE
Počet skupin / kohort
Kohorty a intervence
Skupina / kohortaSkupina / kohorta |
|---|
|
Subjects with a new IPF diagnosis
Subjects with a new diagnosis of IPF established at the time of enrollment in the registry |
|
Subjects with a non-IPF ILD diagnosis
Subjects with a diagnosis of a non-IPF ILD of any duration, including, but not limited to Idiopathic Non-Specific Interstitial Pneumonia (iNSIP), Unclassifiable Idiopathic Interstitial Pneumonias (IIPs), Interstitial Pneumonia with Autoimmune Features (IPAF), Autoimmune ILDs such as Rheumatoid Arthritis (RA-ILD) and Systemic Sclerosis (SSc-ILD), Chronic Hypersensitivity Pneumonitis (HP), Sarcoidosis or Exposure-related ILDs such as asbestosis with progressive phenotype |
|
New Subjects with a new IPF diagnosis
Subjects with a new diagnosis of IPF established at the time of enrollment in the registry not previously enrolled in the registry. |
Co je měření studie?
Primární výstupní opatření
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Data on natural history of IPF & non-IPF chronic fibrosing ILD
Časové okno: End of Study (3 years after last patient will be enrolled)
|
Characterize and describe the natural history of patients with a recent confirmed diagnosis of IPF, with emphasis on demographics, co-morbidities, medications, and risks for disease progression or death. |
End of Study (3 years after last patient will be enrolled)
|
|
Data on current practice patterns for diagnosis of IPF & non-IPF chronic fibrosing ILD
Časové okno: End of Study (3 years after last patient will be enrolled)
|
Understand the current practice patterns for diagnosis of IPF & non-IPF chronic fibrosing ILD |
End of Study (3 years after last patient will be enrolled)
|
|
Data on impact of IPF & non- IPF chronic fibrosing ILD on patient quality of life.
Časové okno: End of Study (3 years after last patient will be enrolled)
|
Describe the impact of IPF & non- IPF chronic fibrosing ILD on patient quality-of-life (QOL). |
End of Study (3 years after last patient will be enrolled)
|
|
Blood samples for future research.
Časové okno: End of Study (3 years after last patient will be enrolled)
|
Collect longitudinal bio-samples for future research on disease presentation, progression, and subject response to clinical interventions. |
End of Study (3 years after last patient will be enrolled)
|
|
HRCT images for future research (for non-IPF chronic fibrosing ILD, and new IPF patients cohort)
Časové okno: End of Study (3 years after last patient will be enrolled)
|
Collect longitudinal HRCT images for future research |
End of Study (3 years after last patient will be enrolled)
|
Sekundární výstupní opatření
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Data on management practices compared to existing guidelines.
Časové okno: End of Study (3 years after last patient will be enrolled)
|
Compare disease-specific management practices with existing guidelines. |
End of Study (3 years after last patient will be enrolled)
|
|
Data on center-specific practices on outcomes.
Časové okno: End of Study (3 years after last patient will be enrolled)
|
Determine the influence of center-specific practices on patient outcomes. |
End of Study (3 years after last patient will be enrolled)
|
Spolupracovníci a vyšetřovatelé
Sponzor
Sponzor
Spolupracovníci
Spolupracovníci
Vyšetřovatelé
Vyšetřovatelé
- Vrchní vyšetřovatel: Scott Palmer, MD, Duke Clinical Research Institute, Duke University
Publikace a užitečné odkazy
Obecné publikace
- Swaminathan AC, Hellkamp AS, Neely ML, Bender S, Paoletti L, White ES, Palmer SM, Whelan TPM, Dilling DF; Idiopathic Pulmonary Fibrosis Prospective Outcomes Registry investigators. Disparities in Lung Transplant among Patients with Idiopathic Pulmonary Fibrosis: An Analysis of the IPF-PRO Registry. Ann Am Thorac Soc. 2022 Jun;19(6):981-990. doi: 10.1513/AnnalsATS.202105-589OC.
- Kim HJ, Snyder LD, Neely ML, Hellkamp AS, Hotchkin DL, Morrison LD, Bender S, Leonard TB, Culver DA; IPF-PRO Registry investigators. Clinical Outcomes of Patients with Combined Idiopathic Pulmonary Fibrosis and Emphysema in the IPF-PRO Registry. Lung. 2022 Feb;200(1):21-29. doi: 10.1007/s00408-021-00506-x. Epub 2022 Jan 7.
- de Andrade JA, Kulkarni T, Neely ML, Hellkamp AS, Case AH, Culver DA, Guntupalli K, Bender S, Conoscenti CS, Snyder LD; IPF-PRO Registry Investigators. Associations between resources and practices of ILD centers and outcomes in patients with idiopathic pulmonary fibrosis: data from the IPF-PRO Registry. Respir Res. 2022 Jan 7;23(1):3. doi: 10.1186/s12931-021-01921-7.
- Kim HJ, Snyder LD, Adegunsoye A, Neely ML, Bender S, White ES, Conoscenti CS, Strek ME; IPF-PRO Registry Investigators. Hospitalizations in patients with idiopathic pulmonary fibrosis. Respir Res. 2021 Sep 30;22(1):257. doi: 10.1186/s12931-021-01851-4.
- Salisbury ML, Conoscenti CS, Culver DA, Yow E, Neely ML, Bender S, Hartmann N, Palmer SM, Leonard TB; IPF-PRO Registry principal investigators as follows. Antifibrotic Drug Use in Patients with Idiopathic Pulmonary Fibrosis. Data from the IPF-PRO Registry. Ann Am Thorac Soc. 2020 Nov;17(11):1413-1423. doi: 10.1513/AnnalsATS.201912-880OC.
- Fan Y, Bender SD, Conoscenti CS, Davidson-Ray L, Cowper PA, Palmer SM, de Andrade JA; IPF-PRO Registry Investigators. Hospital-Based Resource Use and Costs Among Patients With Idiopathic Pulmonary Fibrosis Enrolled in the Idiopathic Pulmonary Fibrosis Prospective Outcomes (IPF-PRO) Registry. Chest. 2020 Jun;157(6):1522-1530. doi: 10.1016/j.chest.2019.12.041. Epub 2020 Jan 29.
- O'Brien EC, Hellkamp AS, Neely ML, Swaminathan A, Bender S, Snyder LD, Culver DA, Conoscenti CS, Todd JL, Palmer SM, Leonard TB; IPF-PRO Registry investigators. Disease Severity and Quality of Life in Patients With Idiopathic Pulmonary Fibrosis: A Cross-Sectional Analysis of the IPF-PRO Registry. Chest. 2020 May;157(5):1188-1198. doi: 10.1016/j.chest.2019.11.042. Epub 2020 Jan 15.
- Todd JL, Neely ML, Overton R, Durham K, Gulati M, Huang H, Roman J, Newby LK, Flaherty KR, Vinisko R, Liu Y, Roy J, Schmid R, Strobel B, Hesslinger C, Leonard TB, Noth I, Belperio JA, Palmer SM; IPF-PRO Registry investigators. Peripheral blood proteomic profiling of idiopathic pulmonary fibrosis biomarkers in the multicentre IPF-PRO Registry. Respir Res. 2019 Oct 22;20(1):227. doi: 10.1186/s12931-019-1190-z.
- Snyder L, Neely ML, Hellkamp AS, O'Brien E, de Andrade J, Conoscenti CS, Leonard T, Bender S, Gulati M, Culver DA, Kaner RJ, Palmer S, Kim HJ; IPF-PRO Registry investigators. Predictors of death or lung transplant after a diagnosis of idiopathic pulmonary fibrosis: insights from the IPF-PRO Registry. Respir Res. 2019 May 30;20(1):105. doi: 10.1186/s12931-019-1043-9.
- O'Brien EC, Durheim MT, Gamerman V, Garfinkel S, Anstrom KJ, Palmer SM, Conoscenti CS. Rationale for and design of the Idiopathic Pulmonary Fibrosis-PRospective Outcomes (IPF-PRO) registry. BMJ Open Respir Res. 2016 Jan 11;3(1):e000108. doi: 10.1136/bmjresp-2015-000108. eCollection 2016.
- Swaminathan AC, Weber JM, Todd JL, Palmer SM, Neely ML, Whelan TP, Kim GHJ, Leonard TB, Goldin J. Extent of lung fibrosis is of greater prognostic importance than HRCT pattern in patients with progressive pulmonary fibrosis: data from the ILD-PRO registry. Respir Res. 2025 Feb 28;26(1):73. doi: 10.1186/s12931-025-03136-6.
- Oldham JM, Neely ML, Wojdyla DM, Gulati M, Li P, Patel DC, Palmer SM, Todd JL; IPF-PRO Registry Investigators. Changes in Lung Function and Mortality Risk in Patients With Idiopathic Pulmonary Fibrosis. Chest. 2025 Aug;168(2):415-422. doi: 10.1016/j.chest.2025.02.018. Epub 2025 Feb 26.
- Sack C, Wojdyla DM, MacMurdo MG, Gassett A, Kaufman JD, Raghu G, Redlich CA, Li P, Olson AL, Leonard TB, Todd JL, Neely ML, Snyder LD, Gulati M; IPF-PRO Registry investigators. Long-Term Air Pollution Exposure and Severity of Idiopathic Pulmonary Fibrosis: Data from the Idiopathic Pulmonary Fibrosis Prospective Outcomes (IPF-PRO) Registry. Ann Am Thorac Soc. 2025 Mar;22(3):378-386. doi: 10.1513/AnnalsATS.202404-382OC.
- Wang L, Wu P, Liu Y, Patel DC, Leonard TB, Zhao H. Clustering-aided prediction of outcomes in patients with idiopathic pulmonary fibrosis. Respir Res. 2024 Oct 23;25(1):383. doi: 10.1186/s12931-024-03015-6.
- Lobo LJ, Liu Y, Li P, Ramaswamy M, Swaminathan AC, Veeraraghavan S, Fan Y, Neely ML, Palmer SM, Olson AL; ILD-PRO Registry investigatorsdagger. Design and baseline characteristics of the ILD-PRO registry in patients with progressive pulmonary fibrosis. BMC Pulm Med. 2024 Sep 27;24(1):468. doi: 10.1186/s12890-024-03247-8.
- Summer R, Todd JL, Neely ML, Lobo LJ, Namen A, Newby LK, Shafazand S, Suliman S, Hesslinger C, Keller S, Leonard TB, Palmer SM, Ilkayeva O, Muehlbauer MJ, Newgard CB, Roman J. Circulating metabolic profile in idiopathic pulmonary fibrosis: data from the IPF-PRO Registry. Respir Res. 2024 Jan 25;25(1):58. doi: 10.1186/s12931-023-02644-7.
- Neely ML, Hellkamp AS, Bender S, Todd JL, Liesching T, Luckhardt TR, Oldham JM, Raj R, White ES, Palmer SM. Lung function trajectories in patients with idiopathic pulmonary fibrosis. Respir Res. 2023 Aug 24;24(1):209. doi: 10.1186/s12931-023-02503-5.
- Ruan P, Todd JL, Zhao H, Liu Y, Vinisko R, Soellner JF, Schmid R, Kaner RJ, Luckhardt TR, Neely ML, Noth I, Porteous M, Raj R, Safdar Z, Strek ME, Hesslinger C, Palmer SM, Leonard TB, Salisbury ML. Integrative multi-omics analysis reveals novel idiopathic pulmonary fibrosis endotypes associated with disease progression. Respir Res. 2023 May 31;24(1):141. doi: 10.1186/s12931-023-02435-0.
- Menon AA, Gansen B, Mulder H, Neely ML, Papavasileiou P, Salisbury ML, Southern BD, Hesslinger C, Leonard TB, Meissner F, Todd JL. Mass spectrometry-based peripheral blood proteomics for biomarker discovery in idiopathic pulmonary fibrosis. Respir Res. 2025 Oct 22;26(1):294. doi: 10.1186/s12931-025-03377-5.
- Shetty S, Swaminathan AC, Li P, Neely ML, Olson AL, Snyder LD; ILD-PRO Registry investigators. Workplace Productivity Loss in Patients with Progressive Pulmonary Fibrosis: Data from the ILD-PRO Registry. Lung. 2026 May 27;204(1):32. doi: 10.1007/s00408-026-00895-x.
- Swaminathan AC, Mulder H, Neely ML, Schmid R, Belperio JA, Patel NM, Palmer SM, Todd JL. Expression of complement pathway genes is associated with progression of idiopathic pulmonary fibrosis. Respir Res. 2026 Mar 25;27(1):196. doi: 10.1186/s12931-026-03641-2.
- Neely ML, Todd JL, Snyder LD, Li P, Olson AL; IPF-PRO Registry Investigators *. Trajectories of Health-Related Quality of Life in Patients With Idiopathic Pulmonary Fibrosis. CHEST Pulm. 2024 Dec 27;3(4):100133. doi: 10.1016/j.chpulm.2024.100133. eCollection 2025 Dec.
- MacMurdo MG, Wojdyla DM, Gassett A, Kaufman JD, Raghu G, Redlich CA, Patel DC, Neely ML, Snyder LD, Gulati M, Sack C; IPF-PRO Registry investigators. Short-term air pollution exposure and hospitalizations in idiopathic pulmonary fibrosis: data from the IPF-PRO Registry. Ann Am Thorac Soc. 2026 Sep 12:aaoag285. doi: 10.1093/annalsats/aaoag285. Online ahead of print.
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Začátek studia
Primární dokončení (Odhadovaný)
Primární dokončení
Dokončení studie (Odhadovaný)
Dokončení studie
Termíny zápisu do studia
První předloženo
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Odhadovaný)
První zveřejněno
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Poslední zveřejněná aktualizace
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
Další relevantní podmínky MeSH
Další identifikační čísla studie
Další identifikační čísla studie
- Pro00046131
- 1199.174 (Jiný identifikátor: DCRI)
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .